Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

Many Mounjaro users have considered making the swap after Eli Lilly announced prices would be increasing in the UK by 170 ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.